FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1511277433> ?p ?o ?g. }

• W1511277433 endingPage "e1016704" @default.
• W1511277433 startingPage "e1016704" @default.
• W1511277433 abstract "Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, however, is problematic. We report the first study providing outcome data for this group of patients with poor prognosis. To prevent another relapse, HR-NB patients in second or later CR/VGPR received the anti-GD2 murine antibody 3F8 plus granulocyte-macrophage colony-stimulating factor plus isotretinoin in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 patients, the trial was amended to allow patients who developed human anti-mouse antibody (HAMA) to receive rituximab to ablate HAMA with or without low-dose maintenance chemotherapy until immunotherapy could resume. For the total of 101 study patients, 5-year PFS and overall survival (OS) rates were 33% ± 5% and 48% ± 5%, respectively. Among the 33 long-term progression-free survivors, 19 had MYCN amplification, 19 had previously received anti-GD2 immunotherapy plus isotretinoin (as first-line therapy), and 15 never received maintenance chemotherapy. In a multivariate analysis of prognostic factors, only absence of minimal residual disease in bone marrow after 2 cycles of immunotherapy and before initiation of isotretinoin or anti-HAMA therapy was significantly favorable for both PFS and OS. Therefore, long-term PFS is possible for HR-NB patients who achieve at least a second CR/VGPR and receive consolidation that includes anti-GD2 immunotherapy plus isotretinoin, even if the patients received these biological treatments before relapse. Results from this prospective study will aid in the development of future Phase II studies for this growing ultra high-risk patient population." @default.
• W1511277433 created "2016-06-24" @default.
• W1511277433 creator A5031172839 @default.
• W1511277433 creator A5034081882 @default.
• W1511277433 creator A5034325765 @default.
• W1511277433 creator A5043729995 @default.
• W1511277433 creator A5050680844 @default.
• W1511277433 creator A5053307625 @default.
• W1511277433 creator A5058950476 @default.
• W1511277433 creator A5083817841 @default.
• W1511277433 date "2015-05-22" @default.
• W1511277433 modified "2023-09-25" @default.
• W1511277433 title "Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2immunotherapy and isotretinoin: a prospective Phase II study" @default.
• W1511277433 cites W1519295343 @default.
• W1511277433 cites W1574327664 @default.
• W1511277433 cites W1935226228 @default.
• W1511277433 cites W1936567301 @default.
• W1511277433 cites W1940650862 @default.
• W1511277433 cites W1960710326 @default.
• W1511277433 cites W1966020001 @default.
• W1511277433 cites W1969208169 @default.
• W1511277433 cites W1985200617 @default.
• W1511277433 cites W1993428519 @default.
• W1511277433 cites W1993940563 @default.
• W1511277433 cites W2007680507 @default.
• W1511277433 cites W2012687605 @default.
• W1511277433 cites W2015214465 @default.
• W1511277433 cites W2019122836 @default.
• W1511277433 cites W2055201556 @default.
• W1511277433 cites W2068512864 @default.
• W1511277433 cites W2095296988 @default.
• W1511277433 cites W2096287682 @default.
• W1511277433 cites W2096398040 @default.
• W1511277433 cites W2099134748 @default.
• W1511277433 cites W2101042741 @default.
• W1511277433 cites W2102118318 @default.
• W1511277433 cites W2104684902 @default.
• W1511277433 cites W2106568960 @default.
• W1511277433 cites W2110788947 @default.
• W1511277433 cites W2111733282 @default.
• W1511277433 cites W2112654701 @default.
• W1511277433 cites W2121146521 @default.
• W1511277433 cites W2127478952 @default.
• W1511277433 cites W2130465135 @default.
• W1511277433 cites W2130686884 @default.
• W1511277433 cites W2132154679 @default.
• W1511277433 cites W2136462971 @default.
• W1511277433 cites W2136574608 @default.
• W1511277433 cites W2137648684 @default.
• W1511277433 cites W2137747512 @default.
• W1511277433 cites W2138216545 @default.
• W1511277433 cites W2140839532 @default.
• W1511277433 cites W2151310238 @default.
• W1511277433 cites W2155614959 @default.
• W1511277433 cites W2327522594 @default.
• W1511277433 doi "https://doi.org/10.1080/2162402x.2015.1016704" @default.
• W1511277433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4485744" @default.
• W1511277433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26140243" @default.
• W1511277433 hasPublicationYear "2015" @default.
• W1511277433 type Work @default.
• W1511277433 sameAs 1511277433 @default.
• W1511277433 citedByCount "46" @default.
• W1511277433 countsByYear W15112774332016 @default.
• W1511277433 countsByYear W15112774332017 @default.
• W1511277433 countsByYear W15112774332018 @default.
• W1511277433 countsByYear W15112774332019 @default.
• W1511277433 countsByYear W15112774332020 @default.
• W1511277433 countsByYear W15112774332021 @default.
• W1511277433 countsByYear W15112774332022 @default.
• W1511277433 countsByYear W15112774332023 @default.
• W1511277433 crossrefType "journal-article" @default.
• W1511277433 hasAuthorship W1511277433A5031172839 @default.
• W1511277433 hasAuthorship W1511277433A5034081882 @default.
• W1511277433 hasAuthorship W1511277433A5034325765 @default.
• W1511277433 hasAuthorship W1511277433A5043729995 @default.
• W1511277433 hasAuthorship W1511277433A5050680844 @default.
• W1511277433 hasAuthorship W1511277433A5053307625 @default.
• W1511277433 hasAuthorship W1511277433A5058950476 @default.
• W1511277433 hasAuthorship W1511277433A5083817841 @default.
• W1511277433 hasBestOaLocation W15112774331 @default.
• W1511277433 hasConcept C121608353 @default.
• W1511277433 hasConcept C126322002 @default.
• W1511277433 hasConcept C141071460 @default.
• W1511277433 hasConcept C143998085 @default.
• W1511277433 hasConcept C16005928 @default.
• W1511277433 hasConcept C2776285725 @default.
• W1511277433 hasConcept C2776694085 @default.
• W1511277433 hasConcept C2777673923 @default.
• W1511277433 hasConcept C2777701055 @default.
• W1511277433 hasConcept C2778283404 @default.
• W1511277433 hasConcept C2780739268 @default.
• W1511277433 hasConcept C31760486 @default.
• W1511277433 hasConcept C71924100 @default.
• W1511277433 hasConceptScore W1511277433C121608353 @default.
• W1511277433 hasConceptScore W1511277433C126322002 @default.
• W1511277433 hasConceptScore W1511277433C141071460 @default.
• W1511277433 hasConceptScore W1511277433C143998085 @default.
• W1511277433 hasConceptScore W1511277433C16005928 @default.

• next